Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

被引：21
|
作者：
Lu Shuqing [1 ]
Yang Jianmin [1 ]
Huang Chongmei [1 ]
Cheng Hui [1 ]
Wang, Jianmin [1 ]
机构：
[1] Second Mil Med Univ, Changhai Hosp, Dept Hematol, Shanghai 200433, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY | 2011年 / 39卷 / 12期
关键词：
CELLS; LINE; OVEREXPRESSION; MUTATION;
D O I：
10.1016/j.exphem.2011.09.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1117 / 1118
页数：2
相关论文
共 19 条
  • [1] Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib
    Barrio, Santiago
    Stuhmer, Thorsten
    Teufel, Eva
    Barrio-Garcia, Clara
    Chatterjee, Manik
    Schreder, Martin
    Das Gupta, Mithun
    Rosenwald, Andreas
    Tibes, Raoul
    Braggio, Esteban
    Stewart, A. Keith
    Bargou, Ralf C.
    Einsele, Hermann
    Kortum, K. Martin
    BLOOD, 2016, 128 (22)
  • [2] AMPLIFICATION AND OVEREXPRESSION OF THE PSMB5 GENE CONTRIBUTE TO BORTEZOMIB RESISTANCE IN RE-TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
    Altavilla, Giuseppe
    Arrigo, Carmela
    Sauta, Maria Grazia
    Galletti, Giuseppe
    Gnani, Alessandro
    Pettineo, Giuseppe
    Buemi, Barbara
    Pitini, Vincenzo
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma
    Altavilla, G.
    Arrigo, C.
    Marabello, G.
    Galletti, G.
    Santarpia, M.
    Sauta, M.
    Pitini, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
    Allmeroth, Kira
    Horn, Moritz
    Kroef, Virginia
    Miethe, Stephan
    Mueller, Roman-Ulrich
    Denzel, Martin S.
    LEUKEMIA, 2021, 35 (03) : 887 - 892
  • [5] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
    Kira Allmeroth
    Moritz Horn
    Virginia Kroef
    Stephan Miethe
    Roman-Ulrich Müller
    Martin S. Denzel
    Leukemia, 2021, 35 : 887 - 892
  • [6] The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
    Robak, Pawel
    Jarych, Dariusz
    Mikulski, Damian
    Drozdz, Izabela
    Weglowska, Edyta
    Kotkowska, Aleksandra
    Misiewicz, Malgorzata
    Smolewski, Piotr
    Stawiski, Konrad
    Fendler, Wojciech
    Szemraj, Janusz
    Robak, Tadeusz
    CANCERS, 2021, 13 (05) : 1 - 17
  • [7] The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
    Zhang, Quane
    Wang, Yifan
    Shi, Wenting
    Chen, Yue
    He, Zhengmei
    Yu, Liang
    Wang, Chunling
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [8] Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study
    Pula, Anna
    Robak, Tadeusz
    Drozdz, Izabela
    Stawiski, Konrad
    Rycerz, Aleksander
    Misiewicz, Malgorzata
    Robak, Pawel
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 257 - 264
  • [9] Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug A case report
    Zhang, Xuzhao
    Liang, Yun
    Li, Xian
    Wang, Weiqin
    Tong, Jiefeng
    Xu, Yang
    MEDICINE, 2020, 99 (40) : E22642
  • [10] The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness
    Lee, Ji Hyun
    Kim, Sung-Hyun
    Huh, Seok Jae
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Lee, Won-Sik
    Lee, Yoojin
    Lee, Ho Sup
    BLOOD, 2018, 132
12